Hirudo polypeptide with functions of antithrombus and brain nerve cell protection and application of hirudo polypeptide

A brain nerve cell, leech polypeptide technology, applied in extracellular fluid diseases, peptides, blood diseases, etc., can solve problems such as unclear active ingredients, achieve the effect of improving neurobehavior, reducing the formation of thrombus in the body, and being easy to prepare in large quantities

Active Publication Date: 2019-11-12
JINAN UNIVERSITY
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported in the literature that leech extract has antithrombotic effects, regulates the expression of coagulation-related factors in endothelial cells (Chinese Journal of Arteriosclerosis, 2017

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hirudo polypeptide with functions of antithrombus and brain nerve cell protection and application of hirudo polypeptide
  • Hirudo polypeptide with functions of antithrombus and brain nerve cell protection and application of hirudo polypeptide
  • Hirudo polypeptide with functions of antithrombus and brain nerve cell protection and application of hirudo polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1 Separation of polypeptide whitmantides A-C

[0056] (1) Leech dried 3 kg of the whole body, washed with physiological saline, soaked and crushed the homogenate, the homogenate was frozen and thawed to obtain the extract. The obtained extract is processed by an ultrafiltration membrane with a molecular weight cut-off of 50KDa, and the ultrafiltrate with a molecular weight of less than 50KDa is collected. After the obtained ultrafiltrate is solid-phase desalinated, it is concentrated under reduced pressure or freeze-dried to obtain the total extract (13g) . At 4~8℃, the total extract was separated by gel Sephadex G25. Ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) method was used for analysis and tracking detection, and the fractions containing peptide compounds were collected, concentrated under reduced pressure or vacuum dried to obtain peptide-enriched fractions (10g).

[0057] (2) Take the polypeptide-enriched part in step (1) and perf...

Embodiment 2

[0061] Example 2 Structural characterization of the polypeptide whitmantide A

[0062] The polypeptide whitmantide A prepared in Example 1 is an amorphous powder with UV (H 2 O)λ max (logε): 195(3.20). IR(KBr)ν max :3275.5,2960.2,1657.52,1541.81cm -1 . HR-ESI-MS m / z 658.4155[M+H] + (calcd forC 30 H 56 N 7 O 9 :658.4140). The Edman degradation method was used to sequence the N-terminal of whitmantide A, and the amino acid sequence was determined to be NH 2 -Leu-Leu-Ser-Gly-Val-Leu-Gly-COOH. The MS / MS secondary mass spectrum showed that the a, b, and y ion fragments of the compound were consistent with its amino acid sequence. The above results further verified the amino acid sequence of whitmantide A. Marfey method analysis showed that whitmantide A contained two D-type leucine and one L-type leucine, and other chiral amino acids were all L-type. The absolute configuration of whitmantide A was determined by solid-phase synthesis. There are three arrangements for the positions...

Embodiment 3

[0063] Example 3 Structural characterization of the polypeptide whitmantide B

[0064] The polypeptide whitmantide B prepared in Example 1 is an amorphous powder, UV (H 2 O)λ max (logε): 196(3.18). IR(KBr)ν max :3275.5,2957.3,1640.16,1544.7,1132.97cm -1 ; HR-ESI-MS m / z715.4331[M+H] + (calcd for C 32 H 59 N 8 O 10 :715.4354). The Edman degradation method was used to sequence the N-terminal of whitmantide B, and the amino acid sequence was determined to be NH 2 -Leu-Leu-Ser-Gly-Val-Leu-Gly-Gly-COOH. The MS / MS secondary mass spectrum showed that the a, b, and y ion fragments of the compound were consistent with its amino acid sequence. The above results further verified the amino acid sequence of whitmantide B. The Marfey method analysis results show that whitmantide B contains two D-type leucine and one L-type leucine, and the other chiral amino acids are all L-type. The absolute configuration of whitmantide B was determined by solid-phase synthesis. There are three arrangement...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Average granularityaaaaaaaaaa
Login to view more

Abstract

The invention discloses hirudo polypeptide with functions of antithrombus and brain nerve cell protection and application of the hirudo polypeptide, and relates to the fields of traditional Chinese medicine, natural medicine and health care products. The structure of the hirudo polypeptide is presented as a formula I, human umbilical vein endothelial cell expressing vascular hemophilia factor (vWF) and a plasminogen activator inhibitor-1(PAI-1) can be significantly lowered at the low concentration of the hirudo polypeptide, the survival rate of nerve cells after oxygen and glucose deprivationis increased, platelet aggregation in vitro is inhibited, the plasma recalcification time is prolonged, formation of thrombi in vivo is reduced, neurobehavior after cerebral infarction of a rat is improved, encephaledema is relieved, the area of cerebral infarction is reduced, the toxicity is low, good application prospects are achieved, and the hirudo polypeptide can be used for preparing medicine or health care products for treating or adjuvant therapy of cardiovascular and cerebrovascular diseases such as atherosclerosis, thrombi and cerebral post-stroke nerve function deficit. The formulaI is NH2-Leu-D-Leu-Ser-Gly-Val-R whitmantide A: R=D-Leu-Gly-COOHwhitmantide B: R=D-Leu-Gly-Gly-COOH whitmantide C: R=COOH.

Description

Technical field [0001] The invention relates to the fields of traditional Chinese medicine, natural medicine and health care products, in particular to a class of leech polypeptides with antithrombotic and brain nerve cell protection effects and applications thereof. Background technique [0002] According to statistics from the World Health Organization, cardiovascular and cerebrovascular diseases are the world's number one cause of death. Atherosclerosis, stroke, myocardial infarction and hemiplegia are common cardiovascular and cerebrovascular diseases. Clinical treatment drugs for cardiovascular diseases have many adverse reactions such as drug resistance and high bleeding risk, and there is currently a lack of effective post-stroke neurological repair drugs. Polypeptides have good biocompatibility, strong specificity, low toxicity, are not easy to accumulate in the body, and have less interaction with other components, but they have the defect of easy enzymatic inactivation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K7/06A61K38/08A61P7/02A61P9/10
CPCA61K38/00A61P7/02A61P9/10C07K7/06
Inventor 叶文才王磊张紫月
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap